Cartesian Therapeutics (RNAC) Interest & Investment Income (2016 - 2026)
Cartesian Therapeutics (RNAC) has disclosed Interest & Investment Income for 12 consecutive years, with $1.0 million as the latest value for Q1 2026.
- For Q1 2026, Interest & Investment Income fell 49.08% year-over-year to $1.0 million; the TTM value through Mar 2026 reached $5.6 million, down 32.14%, while the annual FY2025 figure was $6.6 million, 10.93% down from the prior year.
- Interest & Investment Income hit $1.0 million in Q1 2026 for Cartesian Therapeutics, down from $1.3 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $2.6 million in Q3 2024 and bottomed at $15000.0 in Q1 2022.
- Average Interest & Investment Income over 5 years is $1.3 million, with a median of $1.3 million recorded in 2025.
- Year-over-year, Interest & Investment Income surged 12577.78% in 2022 and then plummeted 49.08% in 2026.
- Cartesian Therapeutics' Interest & Investment Income stood at $1.1 million in 2022, then decreased by 17.62% to $940000.0 in 2023, then soared by 161.06% to $2.5 million in 2024, then plummeted by 48.33% to $1.3 million in 2025, then decreased by 19.09% to $1.0 million in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods came in at $1.0 million, $1.3 million, and $1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.